Mixed connective tissue disease

Best Practice and Research: Clinical Rheumatology

Volumn 30, Issue 1, 2016, Pages 95-111

  Gunnarsson, Ragnar ^a   Hetlevik, Siri Opsahl ^b   Lilleby, Vibke ^a   Molberg, Øyvind ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Dermatomyositis; Genetics; Interstitial pulmonary fibrosis; Mixed connective tissue disease; Myositis; Polymyositis; Pulmonary hypertension; Systemic lupus erythematosus; Systemic sclerosis; U1 small nuclear ribonucleoprotein

Indexed keywords

AMLODIPINE; AZATHIOPRINE; BOSENTAN; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FELODIPINE; GLYCERYL TRINITRATE; HYDROXYCHLOROQUINE; ILOPROST; ISRADIPINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; NIFEDIPINE; SMALL NUCLEAR RIBONUCLEOPROTEIN; U1 SMALL NUCLEAR RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY;

ALOPECIA; ARTHRALGIA; ARTHRITIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; GASTROINTESTINAL DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; MIXED CONNECTIVE TISSUE DISEASE; MORTALITY; MYOSITIS; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; HYPERTENSION, PULMONARY; IMMUNOLOGY; RAYNAUD DISEASE;

ANTIBODIES, ANTINUCLEAR; HUMANS; HYPERTENSION, PULMONARY; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; PROGNOSIS; RAYNAUD DISEASE; RIBONUCLEOPROTEIN, U1 SMALL NUCLEAR;

EID: 84964355198     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2016.03.002     Document Type: Review

References (151)

1. [1] Sharp, G.C., Irvin, W.S., Tan, E.M., et al. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52 (1972), 148–159.
2. [2] Aringer, M., Steiner, G., Smolen, J.S., Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 31 (2005), 411–420.
3. [3] Swanton, J., Isenberg, D., Mixed connective tissue disease: still crazy after all these years. Rheum Dis Clin North Am 31 (2005), 421–436.
4. [4] Sharp, G.C., MCTD: a concept which stood the test of time. Lupus 11 (2002), 333–339.
5. [5] Bennett, R.M., O'Connell, D.J., Mixed connective tissue disease: a clinicopathologic study of 20 cases. Semin Arthritis Rheum 10 (1980), 25–51.
6. [6] Nimelstein, S.H., Brody, S., McShane, D., Holman, H.R., Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 59 (1980), 239–248.
7. [7] Alpert, M.A., Goldberg, S.H., Singsen, B.H., et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 68 (1983), 1182–1193.
8. [8] Sullivan, W.D., Hurst, D.J., Harmon, C.E., et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 63 (1984), 92–107.
9. [9] Lundberg, I., Nyman, U., Pettersson, I., Hedfors, E., Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients. Br J Rheumatol 31 (1992), 811–817.
10. *[10] Burdt, M.A., Hoffman, R.W., Deutscher, S.L., et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 42 (1999), 899–909.
11. [11] Lundberg, I.E., The prognosis of mixed connective tissue disease. Rheum Dis Clin North Am 31 (2005), 535–547 vii–viii.
12. [12] Mier, R.J., Shishov, M., Higgins, G.C., et al. Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am 31 (2005), 483–496 vii.
13. *[13] Gunnarsson, R., Molberg, O., Gilboe, I.M., et al. The prevalence and incidence of mixed connective tissue disease: a national multicentre survey of Norwegian patients. Ann Rheum Dis 70 (2011), 1047–1051.
14. [14] Kotajima, L., Aotsuka, S., Sumiya, M., et al. Clinical features of patients with juvenile onset mixed connective tissue disease: analysis of data collected in a nationwide collaborative study in Japan. J Rheumatol 23 (1996), 1088–1094.
15. [15] Sharp, G.C., Irvin, W.S., May, C.M., et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 295 (1976), 1149–1154.
16. [16] Grader-Beck, T., Wigley, F.M., Raynaud's phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 31 (2005), 465–481 vi.
17. [17] Lundberg, I., Hedfors, E., Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 18 (1991), 1511–1519.
18. [18] Wiener-Kronish, J.P., Solinger, A.M., Warnock, M.L., et al. Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis 124 (1981), 499–503.
19. [19] Prakash, U.B., Luthra, H.S., Divertie, M.B., Intrathoracic manifestations in mixed connective tissue disease. Mayo Clin Proc 60 (1985), 813–821.
20. [20] Prakash, U.B., Respiratory complications in mixed connective tissue disease. Clin Chest Med 19 (1998), 733–746 ix.
21. [21] Kozuka, T., Johkoh, T., Honda, O., et al. Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients. J Thorac Imaging 16 (2001), 94–98.
22. [22] Saito, Y., Terada, M., Takada, T., et al. Pulmonary involvement in mixed connective tissue disease: comparison with other collagen vascular diseases using high resolution CT. J Comput Assist Tomogr 26 (2002), 349–357.
23. [23] Bodolay, E., Szekanecz, Z., Devenyi, K., et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 44 (2005), 656–661.
24. [24] Fagundes, M.N., Caleiro, M.T., Navarro-Rodriguez, T., et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med 103 (2009), 854–860.
25. [25] Lundberg, I.E., Cardiac involvement in autoimmune myositis and mixed connective tissue disease. Lupus 14 (2005), 708–712.
26. [26] Wigley, F.M., Lima, J.A., Mayes, M., et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 52 (2005), 2125–2132.
27. [27] Sharp, G.C., Diagnostic criteria for classification of MCTD. Kasukawa, R., Sharp, G.C., (eds.) Mixed connective tissue disease and anti-nuclear antibodies, 1987, Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, 23–30.
28. [28] Kasukawa, R., Tojo, T., Miyawaki, S., et al. Preliminary diagnostic criteria for classification of mixed connective tissue disease. Kasukawa, R., Sharp, G.C., (eds.) Mixed connective tissue disease and anti-nuclear antibodies, 1987, Elsevier Science Publishers B. V. (Biomedical Division), Amsterdam, 41–47.
29. [29] Alarcón-Segovia, D., Villarreal, M., Classification and diagnostic criteria for mixed connective tissue disease. Kasukawa, R., Sharp, G.C., (eds.) Mixed connective tissue disease and anti-nuclear antibodies, 1987, Elsevier Science Publishers B.V. (Biomedical Division), Amsterdam, 33–40.
30. [30] Kahn, M.F., Appelboom, T., Syndrome de Sharp. Kahn, M.F., Peltier, A.P., Mayer, O., et al. (eds.) Les maladies systémiques, 1991, Flammarion, Paris, 545–556.
31. [31] Bowyer, S., Roettcher, P., Pediatric rheumatology clinic populations in the United States: results of a 3 year survey. Pediatric Rheumatology Database Research Group. J Rheumatol 23 (1996), 1968–1974.
32. [32] Pepmueller, P.H., Lindsley, C.B., Mixed connective tissue disease and undifferentiated connective tissue disease. [Chapter 29] Wedderburn, R.E.P.M.L.B.L.R., (eds.) Textbook of pediatric rheumatology, 7th ed., 2016, W.B. Saunders, Philadelphia, 418–426 e3.
33. *[33] Gunnarsson, R., Aalokken, T.M., Molberg, O., et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 71 (2012), 1966–1972.
34. [34] Greidinger, E.L., Hoffman, R.W., Autoantibodies in the pathogenesis of mixed connective tissue disease. Rheum Dis Clin North Am 31 (2005), 437–450 vi.
35. *[35] Hoffman, R.W., Maldonado, M.E., Immune pathogenesis of mixed connective tissue disease: a short analytical review. Clin Immunol 128 (2008), 8–17.
36. [36] Nyman, U., Lundberg, I., Hedfors, E., Pettersson, I., Recombinant 70-kD protein used for determination of autoantigenic epitopes recognized by anti-RNP sera. Clin Exp Immunol 81 (1990), 52–58.
37. *[37] Flam, S.T., Gunnarsson, R., Garen, T., et al. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology (Oxford, England) 54 (2015), 528–535.
38. [38] Black, C.M., Maddison, P.J., Welsh, K.I., et al. HLA and immunoglobulin allotypes in mixed connective tissue disease. Arthritis Rheum 31 (1988), 131–134.
39. [39] Ruuska, P., Hameenkorpi, R., Forsberg, S., et al. Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. Ann Rheum Dis 51 (1992), 52–55.
40. [40] Kuwana, M., Okano, Y., Kaburaki, J., Inoko, H., Clinical correlations with HLA type in Japanese patients with connective tissue disease and anti-U1 small nuclear RNP antibodies. Arthritis Rheum 39 (1996), 938–942.
41. [41] Paradowska-Gorycka, A., Stypinska, B., Olesinska, M., et al. Association of HLA-DRB1 alleles with susceptibility to mixed connective tissue disease in Polish patients. HLA 87 (2016), 13–18.
42. [42] Wedderburn, L.R., McHugh, N.J., Chinoy, H., et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis–scleroderma overlap. Rheumatology (Oxford) 46 (2007), 1786–1791.
43. [43] Hoffman, R.W., Sharp, G.C., Deutscher, S.L., Analysis of anti-u1 RNA antibodies in patients with connective tissue disease. Arthritis Rheum 38 (1995), 1837–1844.
44. [44] Smolen, J.S., Klippel, J.H., Penner, E., et al. HLA-DR antigens in systemic lupus erythematosus: association with specificity of autoantibody responses to nuclear antigens. Ann Rheum Dis 46 (1987), 457–462.
45. [45] Olsen, M.L., Arnett, F.C., Reveille, J.D., Contrasting molecular patterns of MHC class ii alleles associated with the anti-Sm and anti-RNP precipitin autoantibodies in systemic lupus erythematosus. Arthritis Rheum 36 (1993), 94–104.
46. [46] Kattah, N.H., Kattah, M.G., Utz, P.J., The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev 233 (2010), 126–145.
47. [47] Wigley, F.M., Clinical practice. Raynaud's phenomenon. N Engl J Med 347 (2002), 1001–1008.
48. [48] Maricq, H.R., LeRoy, E.C., D'Angelo, W.A., et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23 (1980), 183–189.
49. [49] Pavlov-Dolijanovic, S., Damjanov, N.S., Stojanovic, R.M., et al. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon. Rheumatol Int, 2011, 1–7.
50. [50] Mugii, N., Hasegawa, M., Matsushita, T., et al. Association between nail-fold capillary findings and disease activity in dermatomyositis. Rheumatology (Oxford) 50 (2011), 1091–1098.
51. [51] Ganczarczyk, M.L., Lee, P., Armstrong, S.K., Nailfold capillary microscopy in polymyositis and dermatomyositis. Arthritis Rheum 31 (1988), 116–119.
52. [52] Olesinska, M., Czuszynska, Z., Felis-Giemza, A., et al. Clinical course and nailfold capillaroscopy patterns of 69 patients with mixed connective tissue disease (MCTD). EULAR Berlin, 2012.
53. *[53] Hajas, A., Szodoray, P., Nakken, B., et al. Clinical course, prognosis, and causes of death in mixed connective tissue disease. J Rheumatol 40 (2013), 1134–1142.
54. [54] Aringer, M., Smolen, J.S., Mixed connective tissue disease: what is behind the curtain?. Best Pract Res Clin Rheumatol 21 (2007), 1037–1049.
55. [55] Kitridou, R.C., Akmal, M., Turkel, S.B., et al. Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study. Semin Arthritis Rheum 16 (1986), 135–145.
56. [56] Hall, S., Hanrahan, P., Muscle involvement in mixed connective tissue disease. Rheum Dis Clin North Am 31 (2005), 509–517 vii.
57. [57] Lundberg, I., Nennesmo, I., Hedfors, E., A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies. Semin Arthritis Rheum 22 (1992), 127–138.
58. [58] Brouwer, R., Hengstman, G.J., Vree Egberts, W., et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60 (2001), 116–123.
59. [59] Pope, J.E., Other manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 31 (2005), 519–533 vii.
60. [60] Udoff, E.J., Genant, H.K., Kozin, F., Ginsberg, M., Mixed connective tissue disease: the spectrum of radiographic manifestations. Radiology 124 (1977), 613–618.
61. [61] Tehranzadeh, J., Ashikyan, O., Dascalos, J., Dennehey, C., MRI of large intraosseous lesions in patients with inflammatory arthritis. AJR Am J Roentgenol 183 (2004), 1453–1463.
62. [62] Aalokken, T.M., Lilleby, V., Soyseth, V., et al. Chest abnormalities in juvenile-onset mixed connective tissue disease: assessment with high-resolution computed tomography and pulmonary function tests. Acta Radiol 50 (2009), 430–436.
63. [63] Prakash, U.B.S., Lungs in mixed connective tissue disease. J Thorac Imaging 7 (1992), 55–61.
64. *[64] Kawano-Dourado, L., Baldi, B.G., Kay, F.U., et al. Pulmonary involvement in long-term mixed connective tissue disease: functional trends and image findings after 10 years. Clin Exp Rheumatol 33 (2015), 234–240.
65. [65] Lefèvre, G., Dauchet, L., Hachulla, E., et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum 65 (2013), 2412–2423.
66. [66] Galie, N., Humbert, M., Vachiery, J.L., et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37 (2016), 67–119.
67. [67] Simonneau, G., Gatzoulis, M.A., Adatia, I., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62 (2013), D34–D41.
68. [68] Condliffe, R., Kiely, D.G., Peacock, A.J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179 (2009), 151–157.
69. [69] Shirai, Y., Yasuoka, H., Okano, Y., et al. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. Rheumatology (Oxford) 51 (2012), 1846–1854.
70. [70] Chung, L., Farber, H.W., Benza, R., et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest 146 (2014), 1494–1504.
71. [71] Magro, C.M., Crowson, A.N., Regauer, S., Mixed connective tissue disease. A clinical, histologic, and immunofluorescence study of eight cases. Am J Dermatopathol 19 (1997), 206–213.
72. [72] Ling, T.C., Johnston, B.T., Esophageal investigations in connective tissue disease: which tests are most appropriate?. J Clin Gastroenterol 32 (2001), 33–36.
73. [73] Lapadula, G., Muolo, P., Semeraro, F., et al. Esophageal motility disorders in the rheumatic diseases: a review of 150 patients. Clin Exp Rheumatol 12 (1994), 515–521.
74. [74] Matsumoto, T., Kobayashi, S., Shimizu, H., et al. The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver 20 (2000), 366–373.
75. [75] Galvan, V.G., Oltra, M.R., Rueda, D., et al. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. Clin Rheumatol 26 (2007), 971–972.
76. [76] Inoue, K., Okajima, T., Tanaka, E., et al. A case of Graves’ disease associated with autoimmune hepatitis and mixed connective tissue disease. Endocr J 46 (1999), 173–177.
77. [77] James, O., Macklon, A.F., Watson, A.J., Primary biliary cirrhosis – a revised clinical spectrum. Lancet 1 (1981), 1278–1281.
78. [78] Hirasaki, S., Koide, N., Ogawa, H., et al. Mixed connective tissue disease associated with idiopathic portal hypertension and chronic thyroiditis. J Gastroenterol 32 (1997), 808–811.
79. [79] Furuya, T., Suzuki, T., Onoda, N., et al. Mixed connective tissue disease associated with protein losing enteropathy: successful treatment with intravenous cyclophosphamide therapy. Intern Med 31 (1992), 1359–1362.
80. [80] Chao, C.T., Lai, C.Y., Chang, P.L., et al. Mixed connective tissue disease with protein-losing enteropathy: discussion of the treatment strategy. J Clin Rheumatol 17 (2011), 286–287.
81. [81] Hung, E.W., Mayes, M.D., Sharif, R., et al. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol 40 (2013), 455–460.
82. [82] Liberski, S.M., McGarrity, T.J., Hartle, R.J., et al. The watermelon stomach: long-term outcome in patients treated with Nd:YAG laser therapy. Gastrointest Endosc 40 (1994), 584–587.
83. [83] Nowicka-Sauer, K., Czuszynska, Z., Majkowicz, M., et al. Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus. Lupus 21 (2012), 927–933.
84. [84] Hajas, A., Szodoray, P., Barath, S., et al. Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol 36 (2009), 1930–1936.
85. [85] Kobayashi, S., Nagase, M., Kimura, M., et al. Renal involvement in mixed connective tissue disease. Report of 5 cases. Am J Nephrol 5 (1985), 282–289.
86. [86] Weening, J.J., D'Agati, V.D., Schwartz, M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15 (2004), 241–250.
87. [87] Gendi, N.S.T., Welsh, K.I., Van Venrooij, W.J., et al. Hla type as a predictor of mixed connective tissue disease differentiation ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 38 (1995), 259–266.
88. [88] van den Hoogen, F.H., Spronk, P.E., Boerbooms, A.M., et al. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. Br J Rheumatol 33 (1994), 1117–1120.
89. [89] Cappelli, S., Bellando Randone, S., Martinovic, D., et al. “To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 41 (2012), 589–598.
90. [90] Arnett, F.C., Edworthy, S.M., Bloch, D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988), 315–324.
91. [91] Bohan, A., Peter, J.B., Bowman, R.L., Pearson, C.M., Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56 (1977), 255–286.
92. [92] Hochberg, M.C., Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 40, 1997, 1725.
93. [93] Petri, M., Orbai, A.-M., Alarcón, G.S., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64 (2012), 2677–2686.
94. [94] Tan, E.M., Cohen, A.S., Fries, J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982), 1271–1277.
95. [95] Masi, A.T., Subcommittee for Scleroderma Criteria of the American Rheumatism Association D, Therapeutic Criteria C. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23 (1980), 581–590.
96. [96] van den Hoogen, F., Khanna, D., Fransen, J., et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65 (2013), 2737–2747.
97. [97] Cutolo, M., Sulli, A., Smith, V., How to perform and interpret capillaroscopy. Best Pract Res Clin Rheumatol 27 (2013), 237–248.
98. [98] Huisstede, B.M., Hoogvliet, P., Paulis, W.D., et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil 92 (2011), 1166–1180.
99. [99] Thompson, A.E., Pope, J.E., Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 44 (2005), 145–150.
100. [100] Pope, J., Fenlon, D., Thompson, A., et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev, 1998, 10.1002/14651858.CD000953 Issue 2. Art. No.: CD000953.
101. [101] Brueckner, C.S., Becker, M.O., Kroencke, T., et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 69 (2010), 1475–1478.
102. [102] Moinzadeh, P., Hunzelmann, N., Krieg, T., Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis. J Am Acad Dermatol 65 (2011), e102–e104.
103. [103] Hartzell, T.L., Makhni, E.C., Sampson, C., Long-term results of periarterial sympathectomy. J Hand Surg Am 34 (2009), 1454–1460.
104. [104] Wasserman, A., Brahn, E., Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomy. Semin Arthritis Rheum 40 (2010), 137–146.
105. [105] Iorio, M.L., Masden, D.L., Higgins, J.P., Botulinum toxin A treatment of Raynaud's phenomenon: a review. Semin Arthritis Rheum 41 (2012), 599–603.
106. [106] Neumeister, M.W., The role of botulinum toxin in vasospastic disorders of the hand. Hand Clin 31 (2015), 23–37.
107. [107] Dhillon, S., Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis. Drugs 69 (2009), 2005–2024.
108. [108] Korn, J.H., Mayes, M., Matucci Cerinic, M., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50 (2004), 3985–3993.
109. [109] Tsifetaki, N., Botzoris, V., Alamanos, Y., et al. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study. J Rheumatol 36 (2009), 1550–1552.
110. [110] Roldan, T., Landzberg, M.J., Deicicchi, D.J., et al. Anticoagulation in patients with pulmonary arterial hypertension: an update on current knowledge. J Heart Lung Transpl 35 (2016), 151–164.
111. [111] Ezedunukwe, I.R., Enuh, H., Nfonoyim, J., Enuh, C.U., Anticoagulation therapy versus placebo for pulmonary hypertension. Cochrane Database Syst Rev, 6, 2014 Cd010695.
112. [112] Nikpour, M., Stevens, W., Proudman, S.M., et al. Should patients with systemic sclerosis-related pulmonary arterial hypertension be anticoagulated?. Intern Med J 43 (2013), 599–603.
113. [113] Henkens, I.R., Hazenoot, T., Boonstra, A., et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 41 (2013), 872–878.
114. [114] Rubin, L.J., Badesch, D.B., Barst, R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002), 896–903.
115. [115] Galie, N., Badesch, D., Oudiz, R., et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46 (2005), 529–535.
116. [116] Galiè, N., Ghofrani, H.A., Torbicki, A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005), 2148–2157.
117. [117] Caravita, S., Wu, S.C., Secchi, M.B., et al. Long-term effects of intermittent iloprost infusion on pulmonary arterial pressure in connective tissue disease. Eur J Intern Med 22 (2011), 518–521.
118. [118] Jing, Z.-C., Yu, Z.-X., Shen, J.-Y., et al. Vardenafil in pulmonary arterial hypertension. Am J Respir Crit Care Med 183 (2011), 1723–1729.
119. [119] Klinger, J.R., Tadalafil for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med 5 (2011), 315–328.
120. [120] Galiè, N., Corris, P.A., Frost, A., et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62 (2013), D60–D72.
121. [121] Granton, J., Mercier, O., De Perrot, M., Management of severe pulmonary arterial hypertension. Semin Respir Crit Care Med 34 (2013), 700–713.
122. [122] Humbert, M., Current challenges in pulmonary hypertension. Semin Respir Crit Care Med 34 (2013), 549–550.
123. [123] Pulido, T., Adzerikho, I., Channick, R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369 (2013), 809–818.
124. [124] Hassoun, P.M., Zamanian, R.T., Damico, R., et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 192 (2015), 1102–1110.
125. [125] Sitbon, O., Channick, R., Chin, K.M., et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373 (2015), 2522–2533.
126. [126] Simonneau, G., Torbicki, A., Hoeper, M.M., et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40 (2012), 874–880.
127. [127] Sharma, K., Selexipag for the treatment of pulmonary arterial hypertension. Expert Rev Respir Med 10 (2016), 1–3.
128. [128] Jais, X., Launay, D., Yaici, A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 58 (2008), 521–531.
129. [129] Dunkley, L., Green, M., Gough, A., Comment on: a case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy response. Rheumatology (Oxford) 46 (2007), 1628–1629.
130. [130] Haroon, M., O'Gradaigh, D., Foley-Nolan, D., A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy. Rheumatology (Oxford) 46 (2007), 718–719.
131. [131] Rudolph, S.E., Kouba, M., Hrdlicka, P., (Trans.) Severe corticoid-refractory autoimmune thrombocytopenia associated with mixed connective tissue disease (Sharp's syndrome). Treatment with rituximab Dtsch Med Wochenschr 134 (2009), 1734–1738.
132. [132] Vela, P., Sivera, F., Batlle-Gualda, E., et al. Severe ischemia following treatment with rituximab in a patient with mixed connective tissue disease: an unusual complication. Lupus 19 (2010), 1005–1006.
133. [133] Gunnarsson, R., Gilboe, I.-M., Garen, T., Molberg, Ø., Evaluating the therapeutic effects of B cell depletion therapy with rituximab in a longitudinal cohort of mixed connective tissue disease patients. [1928] Arthritis Rheum, 2012, S1–S1216 American College of Rheumatology The 76th 2012 Annual Scientific Meeting Washington D.C. USA.
134. [134] Pascual, M., Narváez, J., Espi, G.A., et al. Rituximab in refractory mixed connective tissue disease: an observational study. [277] Arthritis Rheumatol, 67(suppl 10), 2015 [abstract]. Arthritis Rheumatol.
135. [135] Jansson, A.F., Sengler, C., Kuemmerle-Deschner, J., et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 30 (2011), 87–97.
136. [136] Richez, C., Blanco, P., Dumoulin, C., Schaeverbeke, T., Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease. Clin Exp Rheumatol, 23, 2005, 273.
137. [137] Costa, M.F., Said, N.R., Zimmermann, B., Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37 (2008), 381–387.
138. [138] Christopher-Stine, L., Wigley, F., Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol 30 (2003), 2725–2727.
139. [139] Grant, K.D., Adams, L.E., Hess, E.V., Mixed connective tissue disease – a subset with sequential clinical and laboratory features. J Rheumatol 8 (1981), 587–598.
140. [140] Michels, H., Course of mixed connective tissue disease in children. Ann Med 29 (1997), 359–364.
141. [141] Piirainen, H.I., Patients with arthritis and anti-U1-RNP antibodies: a 10-year follow-up. Br J Rheumatol 29 (1990), 345–348.
142. [142] Singsen, B.H., Bernstein, B.H., Kornreich, H.K., et al. Mixed connective tissue disease in childhood. A clinical and serologic survey. J Pediatr 90 (1977), 893–900.
143. *[143] Gunnarsson, R., Andreassen, A.K., Molberg, O., et al. Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature. Rheumatology (Oxford) 52 (2013), 1208–1213.
144. [144] Barst, R.J., Chung, L., Zamanian, R.T., et al. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 144 (2013), 160–168.
145. [145] Nickel, N., Golpon, H., Greer, M., et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 39 (2012), 589–596.
146. [146] Farber, H.W., Miller, D.P., Poms, A.D., et al. FIve-year outcomes of patients enrolled in the reveal registry. Chest 148 (2015), 1043–1054.
147. *[147] Sobanski, V., Giovannelli, J., Lynch, B.M., et al. Characteristics and survival of patients with anti-U1RNP antibodies in connective tissue disease associated pulmonary arterial hypertension. Arthritis Rheumatol 68 (2016), 484–493.
148. *[148] Gunnarsson, R., El-Hage, F., Aaløkken, T.M., et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 55 (2016), 103–108.
149. [149] Fischer, A., Bull, T.M., Steen, V.D., Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res Hob 64 (2012), 303–310.
150. [150] Coghlan, J.G., Denton, C.P., Grunig, E., et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 73 (2014), 1340–1349.
151. [151] Tiddens, H.A., van der Net, J.J., de Graeff-Meeder, E.R., et al. Juvenile-onset mixed connective tissue disease: longitudinal follow-up. J Pediatr 122 (1993), 191–197.